1 / 23

CONTENTS

CONTENTS. General Information Operational Data Consolidated Healthcare Personal Care Property Development Future Strategies. ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR. General Information Shareholders Affiliates and Subsidiaries Current Consolidated Structure. SHAREHOLDERS.

dung
Télécharger la présentation

CONTENTS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CONTENTS • General Information • Operational Data • Consolidated • Healthcare • Personal Care • Property Development • Future Strategies

  2. ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR • General Information • Shareholders • Affiliates and Subsidiaries • Current Consolidated Structure

  3. SHAREHOLDERS

  4. AFFILIATES AND SUBSIDIARIES

  5. CURRENT CONSOLIDATED STRUCTURE EİS • Personal Care • Ecz.-Beiersdorf %50,0 • Ecz.-Girişim Co. %48,1 • Ecz.-Schwarzkopf %47,0 • Other • Ecz. Holding %37,3 • Ecz.Frgn Trd.%26,4 • Vitra Karo %25,0 • Ecz. Inf. Com.%14,0 • Healthcare • Ecz. Pharma. Marketing %99,9 • Ecz. Pharma. Trading %94,7 • Ecz.-Baxter Hospital S. %50,0 • Ecz. Pharma(Cyprus) %50,0 • Ecz.-Monrol %50,0 • Ecz. Health Services %46,5 • Property Development • Ecz. Property Dv. %99,5 • Kanyon AVM %50,0 • Kanyon Office %100,0 • Ormanada Project %50,0

  6. ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR • Operational Data • Consolidated • Healthcare • Personal Care • Property Development

  7. 2009 - 2010 CONSOLIDATED INDICATORS (MIO TRY) 2009 2010 290,2 CONSOLIDATED NET SALES CONSOLIDATED NET PROFIT CONSOLIDATED OPERATING PROFIT

  8. 2009 - 2010 CONSOLIDATED INDICATORS • (MIO TRY)2009 2010 ∆ (%) • Consolidated Total Assets: 2.489 2.662 7 • Consolidated Total Equities: 2.190 2.387 9 • Equities / Assets: 88 90 2

  9. 2010 CONSOLIDATED SEGMENT DEVELOPMENTS – HEALTHCARE– • INDUSTRIAL DEVELOPMENTS • Turkish Republic Social Security Corporation, claiming that with regard to the 2010 medical expenses, the figures agreed with the industry were exceeded, increased public discount by 9.5% in all medicines with a sales price over TRY 10. • Thereby, the public discount ratio of the original medicines without an equivalent was raised to 32.5%, while that of the original medicines with equivalent and the equivalent medicines themselves was raised to 20.5%. • We are taking measures as necessary in an effort to reduce impacts of those resolutions on the operating profitability.

  10. 2010 CONSOLIDATED SEGMENT DEVELOPMENTS – HEALTHCARE– DEVELOPMENTS IN OPERATIONS The new products lauched by Eczacibasi Ilac Pazarlama in 2010 The new products we plan to launch in 2011: The new product portfolios of 2010 and 2011 are expected to have a contribution equal to appr. 25.5 mio TRYon the 2011 net sales

  11. 2010 CONSOLIDATED SEGMENT DEVELOPMENTS – HEALTHCARE – • OPERATIONAL DEVELOPMENTS • Eczacıbaşı-Monrol; • The radiopharmaceutical (FDG) production plant in Istanbul Technopark was completed in 2010. • The FDG production plant investments, continuing in Antalya • and Malatya in Turkey and, in Romania in abroad, will • be completed in 2011. • The endeavors related to acquisition of 99.996% share of Molekuler Goruntuleme Tic. Ve San. A.S. are continuing and is expected to be completed in June 2011. • In 2011, we are planning to establish FDG production plants in Poland and Egypt.

  12. 2009 - 2010 CONSOLIDATED SEGMENT INDICATORS – MEDICAL– (MIO TRY)

  13. MENICON PARTNERSHIP • Eczacıbaşı İlaç Pazarlama, Executed a contract on 01 November 2010 with Menicon, Japan’s first and largest contact lens and lens care products manufacturer, operating in more than 30 countries including Europe, USA and Japan with over 1.000 employees, for marketing and sales rights in Turkey • Supported by a strong licensor, we are now in the ophthalmology business. • (Keratokonus) Menicon lenses are the best lenses in the world with regard to the hard lenses and those manufuctured for personal treatment. • We are targeting a 20% market share in the contact lens and lens care products market, which has an approximate size of 50 mio TRY

  14. 2010 CONSOLIDATED SEGMENT DEVELOPMENTS – PERSONAL CARE– • On the basis of TRY in 2010; • Fast Consumption Products Market 9%*, • Personal Care Market 6,5%, • Cosmetics sub-market grew by 8.6%. • The competition increased in all fields where we operate. (*) AC Nielsen, 2010 Q4 FMCG Track, Total Trade Volume excluding cigarattes, TRY

  15. 2009 - 2010 CONSOLIDATED SEGMENT INDICATORS –PERSONAL CARE- (MIO TRY)

  16. 2010 CONSOLIDATED SEGMENT DEVELOPMENTS – PROPERTY DEVELOPMENT– • KANYON: • EIS owns 100% of the office block and 50% of the Shopping Center. • The Kanyon Shopping Center took its place as a life center in the middle of the city, in addition to being a shopping center, it preserved its quality as the shopping center which offers many renovations thanks to the attempts took place in 2010. • Given the increasing competition in the industry through the new shopping center openings, Kanyon focused on activities which could impose differences (marketing activities, placement of brands with a high customer attraction and traffic potential, reinforcing the brand spectrum) • The number of visitors to Kanyon increased by 9% in 2010.

  17. 2010 CONSOLIDATED SEGMENT DEVELOPMENTS – PROPERTY DEVELOPMENT– • ORMANADA PROJECT: • 50% of the 22 lots covering 196.410 m2 in total is owned by EIS. • The properties are plots with a development license, they are licensed for housing, and partially for commercial purposes. • Total construction area is expected to be about 90 thousand m2. • The construction works were commenced in the last quarter of 2010. • The application and internal design project works carried out by different architectural groups have been completed, and the total number of housing units in the project is assumed to be 270.

  18. 2009 - 2010 CONSOLIDATED SEGMENT INDICATORS – PROPERTY DEVELOPMENT– (M IO TL) % 22 % 49

  19. EIS ECZACIBASI PHARMACEUTICAL AND INDUSTRIAL INVESTMENT CO. • Future Strategies

  20. FUTURE STRATEGIES MEDICAL INDUSTRY • Procuring strong licensors, brands and strategical partnerships, • Acquiring licenses and offering new products to the market in a short tim Focusing particularly on biotechnology products in order to expand our biotech product range, • Establishing new nuclear medicine production plants in or outside Turkey and realize new investments in R&D, • Increasing the number of Evital Units which provide services to patients who need care, • Penetrating new fields in medical industry. • PERSONAL CARE • Continuing our current leadership in the fast consumed products industry • Penetrating to other categories in the “fast consumed products” market, with a focus on “personal care products” which provide synergy.

  21. FUTURE STRATEGIES PROPERTY DEVELOPMENT • Completing the ongoing projects • Developing new commercial properties in the areas with high development potential • BANKING • On 31 December 2009, we applied to Turkish Banking Supervision and Organization Board for the purpose of establishing an Investment Bank. In the event necessary permissions are received after having completed the legal processes, we decided to participate in the bank’s capital by 40%.

  22. THANK YOU VERY MUCH

More Related